Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 21

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 21
---
 that may be acquired by Mr. Alton within 60 days of April 17, 2025 pursuant to options.                                                                                                                                                                                                                                                                                                                                        |
| (16) |     | Includes 190,000 shares that may be acquired by Ms. Park within 60 days of April 17, 2025 pursuant to options.                                                                                                                                                                                                                                                                                                                                         |
| (17) |     | Includes 160,000 shares that may be acquired by Dr. Cannon within 60 days of April 17, 2025 pursuant to options.                                                                                                                                                                                                                                                                                                                                       |
| (18) |     | Includes 138,961 shares that may be acquired by Mr. Swisher within 60 days of April 17, 2025 pursuant to options.                                                                                                                                                                                                                                                                                                                                      |
| (19) |     | Includes 138,750 shares that may be acquired by Mr. Murray within 60 days of April 17, 2025 pursuant to options.                                                                                                                                                                                                                                                                                                                                       |
| (20) |     | Total number of shares includes common stock held by directors, executive officers and entities affiliated with directors and executive officers. See footnotes 7 through 19 above.                                                                                                                                                                                                                                                                    |

<div align='center'>13</div>

### CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Our Audit Committee’s written charter requires that the Audit Committee review and approve or disapprove all related party transactions that are required to be disclosed by Item 404 of Regulation S-K. All related party transactions between us and our executive officers, directors or principal stockholders are reviewed and approved by our Audit Committee or a majority of the independent and disinterested members of our Board to ensure they are on terms no less favorable to us than could be obtained from unaffiliated third parties and have bona fide business purposes. Since January 1, 2024, there were no related party transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K, other than the director and executive compensation arrangements discussed herein.

Severance and Change in Control Agreements. We have entered into severance and change in control agreements with our executive officers. The agreements provide that, if employment is terminated without cause or for good reason regardless of whether it is in connection with a change in control, the executive will continue to receive, for 12 months, his or her base salary and continued health insurance coverage. The agreements also provide for full vesting of the terminated executive’s outstanding equity awards in the event the termination occurs, with or without cause, within 18